This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2022
Presentations
Enfortumab Vedotin | Urothelial Cancer | LBA73
Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin (EV) Monotherapy or in Combination with Pembrolizumab (P) in Previously Untreated Cisplatin-ineligible Patients (pts) with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)